Related Experiment Videos
Beta-blockers are poorly tolerated by the elderly: myth or reality?
1College of Pharmacy, University of Georgia, Athens, Georgia 30602-2354, USA. jcooper@rx.uga.edu
Postgraduate Medicine
|August 12, 2009
Summary
Beta-blocker therapy significantly reduces cardiovascular risks and mortality in older adults. Increased patient education can improve the underutilization of these vital medications in the elderly population.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Background:
- Beta-blocker therapy is proven to reduce mortality and major cardiovascular events in elderly patients.
- Despite comparable benefits to younger populations, beta-blockers are underutilized in older adults.
- This underuse leads to increased mortality and hospitalization rates in the elderly.
Purpose of the Study:
- To highlight the underutilization of beta-blocker therapy in older patients.
- To identify factors contributing to the underuse of beta-blockers in the elderly.
- To emphasize the role of education in improving beta-blocker adherence and outcomes.
Main Methods:
- Literature review on beta-blocker use in geriatrics.
- Analysis of factors influencing medication adherence in older adults.
- Assessment of educational interventions for improving therapeutic outcomes.
Main Results:
- Older patients experience significant cardiovascular benefits from beta-blockers, similar to younger individuals.
- Physiologic changes, comorbidities, polypharmacy, tolerability, and compliance issues contribute to underutilization.
- Educational strategies can address some barriers to widespread use.
Conclusions:
- Beta-blockers remain underutilized in the elderly despite proven efficacy.
- Addressing age-related factors and improving patient education are crucial for optimizing beta-blocker therapy.
- Enhanced understanding and education can improve cardiovascular outcomes in older adults.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...